Bridger Management LLC Sells 6,207 Shares of Alnylam Pharmaceuticals, Inc. $ALNY

Key Points

• Bridger Management LLC has reduced its stake in Alnylam Pharmaceuticals by 15.1%, holding 34,975 shares valued at approximately $9.4 million as of the latest reporting.
• Analysts are optimistic about Alnylam's prospects, with several firms increasing their price targets, including BMO Capital Markets raising it to $360 and Needham & Company boosting it to $478.
• Insider selling has been notable, with EVP Jeffrey V. Poulton and CEO Yvonne Greenstreet selling over $4 million worth of shares collectively, indicating potential concerns or shifts within the company.

Bridger Management LLC trimmed its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 15.1% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 34,975 shares of the biopharmaceutical company's stock after selling 6,207 shares during the quarter. Alnylam Pharmaceuticals accounts for approximately 4.7% of Bridger Management LLC's investment portfolio, making the stock its 9th biggest position. Bridger Management LLC's holdings in Alnylam Pharmaceuticals were worth $9,444,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in ALNY. SVB Wealth LLC purchased a new position in shares of Alnylam Pharmaceuticals in the 1st quarter valued at about $27,000. Park Square Financial Group LLC purchased a new position in shares of Alnylam Pharmaceuticals in the 4th quarter valued at about $28,000. Whipplewood Advisors LLC boosted its stake in shares of Alnylam Pharmaceuticals by 208.8% in the 1st quarter. Whipplewood Advisors LLC now owns 105 shares of the biopharmaceutical company's stock valued at $28,000 after buying an additional 71 shares during the period. Bessemer Group Inc. boosted its stake in shares of Alnylam Pharmaceuticals by 176.9% in the 1st quarter. Bessemer Group Inc. now owns 108 shares of the biopharmaceutical company's stock valued at $29,000 after buying an additional 69 shares during the period. Finally, Colonial Trust Co SC purchased a new position in shares of Alnylam Pharmaceuticals in the 4th quarter valued at about $35,000. Hedge funds and other institutional investors own 92.97% of the company's stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on ALNY shares. Raymond James Financial started coverage on Alnylam Pharmaceuticals in a research report on Wednesday, July 30th. They set an "outperform" rating and a $370.00 target price on the stock. Wall Street Zen lowered Alnylam Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research report on Friday. Needham & Company LLC raised their target price on Alnylam Pharmaceuticals from $377.00 to $478.00 and gave the stock a "buy" rating in a research report on Thursday, July 31st. Wolfe Research raised Alnylam Pharmaceuticals from an "underperform" rating to a "peer perform" rating in a research report on Monday, August 4th. Finally, BMO Capital Markets set a $470.00 target price on Alnylam Pharmaceuticals and gave the stock an "outperform" rating in a research report on Friday. Twenty-two research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $417.38.

Alnylam Pharmaceuticals Stock Performance

ALNY traded down $1.54 during trading on Friday, hitting $452.00. 751,495 shares of the stock were exchanged, compared to its average volume of 1,065,318. The firm has a market capitalization of $59.25 billion, a P/E ratio of -183.00 and a beta of 0.32. Alnylam Pharmaceuticals, Inc. has a 1-year low of $205.87 and a 1-year high of $469.81. The stock has a fifty day moving average price of $387.47 and a two-hundred day moving average price of $309.71. The company has a quick ratio of 2.75, a current ratio of 2.80 and a debt-to-equity ratio of 4.10.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last released its earnings results on Thursday, July 31st. The biopharmaceutical company reported $0.32 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.54) by $0.86. The business had revenue of $773.69 million for the quarter, compared to analyst estimates of $633.54 million. Alnylam Pharmaceuticals had a negative return on equity of 273.52% and a negative net margin of 12.96%.The company's revenue for the quarter was up 17.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.13) earnings per share. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. As a group, sell-side analysts predict that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

Insiders Place Their Bets

In other news, EVP Pushkal Garg sold 1,455 shares of the business's stock in a transaction that occurred on Tuesday, August 19th. The stock was sold at an average price of $458.41, for a total value of $666,986.55. Following the transaction, the executive vice president owned 20,221 shares of the company's stock, valued at approximately $9,269,508.61. The trade was a 6.71% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Jeffrey V. Poulton sold 2,274 shares of the business's stock in a transaction that occurred on Monday, August 18th. The shares were sold at an average price of $453.27, for a total value of $1,030,735.98. Following the completion of the transaction, the executive vice president directly owned 50,121 shares in the company, valued at approximately $22,718,345.67. The trade was a 4.34% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 57,594 shares of company stock valued at $25,551,456. 1.50% of the stock is owned by company insiders.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.